Abstract
Inspections of pharmaceutical market participants to verify their compliance with good practice requirements are integral to good regulatory practices of the Member States of the Eurasian Economic Union (EAEU). The framework for Good Clinical Practice (GCP) inspections is outlined in Decision No. 78 of the Council of the Eurasian Economic Commission of November 3, 2016.This interview with Alla A. TRAPKOVA, Deputy General Director of the Scientific Centre for Expert Evaluation of Medicinal Products of the Ministry of Health of the Russian Federation, provides information on the importance, objectives, and rules of conducting GCP inspections.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
